- New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.[Blood. 2007]
- Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.[Am J Pathol. 1998]
- Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.[Br J Haematol. 2010]
- The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.[Blood. 2009]
Links to materials
Table Name
| Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. [Blood Cells Mol Dis. 2004] Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. [Blood. 2003] Review A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. [Immunol Rev. 2003] Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. [Haematologica. 2004] Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. [Blood. 1998] Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. [Blood. 2002] The bone marrow plasma cell labeling index by flow cytometry. | ||||
|---|---|---|---|---|
| Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. | ||||
| Review A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. | ||||
| Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. | ||||